ZD 9720

Drug Profile

ZD 9720

Latest Information Update: 10 Dec 1999

$50 / €47 *
* $ price applies to USA, Canada and Latin America. € price applies to the rest of the world. Final gross prices may vary according to local VAT.

At a glance

  • Originator AstraZeneca
  • Class Antihyperlipidaemics
  • Mechanism of Action Oxidosqualene cyclase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No

Highest Development Phases

  • Discontinued Hypercholesterolaemia

Most Recent Events

  • 10 Dec 1999 Discontinued-Preclinical for Hypercholesterolaemia in United Kingdom (Unknown route)
  • 07 Apr 1999 Merger of Astra and Zeneca to form AstraZeneca completed.
  • 12 Dec 1997 New profile
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top